Antibodies

30 Oct 2017 Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b
30 Oct 2017 Poster featured at 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Company anticipates filing an IND for FPT155 in mid 2018
30 Oct 2017 Aptevo Therapeutics Presents New Preclinical Data on APVO436 – a Next Generation ADAPTIR™ Bispecific Antibody Candidate
30 Oct 2017 European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma
28 Oct 2017 Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
27 Oct 2017 Treatment Effects Maintained Over Five Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Extension Study After Switching from Interferon Beta-1a
27 Oct 2017 New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis
26 Oct 2017 Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies
26 Oct 2017 Vaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)
26 Oct 2017 FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women with Advanced Ovarian Cancer
25 Oct 2017 Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
24 Oct 2017 Goodwin Biotechnology and For-Robin Collaborated to Generate a Unique Antibody : Drug Conjugate (ADC) that Shows Promise in Enhancing the Treatment of a Variety of Cancers
24 Oct 2017 Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527
24 Oct 2017 FDA Approves Soliris(R) (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)
24 Oct 2017 MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL
23 Oct 2017 Janssen receives two U.S. FDA approvals for Simponi Aria® (golimumab) for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis
19 Oct 2017 OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
18 Oct 2017 Acticor Biotech First-in-Human Clinical Trial in Healthy Volunteers
18 Oct 2017 Merck’s KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with High Levels of PD-L1
17 Oct 2017 ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active
17 Oct 2017 Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA
17 Oct 2017 ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease
17 Oct 2017 US FDA accepts supplemental Biologics License Application for Imfinzi in locally advanced unresectable non-small cell lung cancer
17 Oct 2017 U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review
16 Oct 2017 Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top